Showing 6111-6120 of 19385 results for "".
Encouraging CPR Participation from Bystanders
https://reachmd.com/programs/clinicians-roundtable/encouraging-cpr-participation-from-bystanders/2927/In cases of out-of-hospital sudden cardiac arrest, bystanders are now formally encouraged to bypass full cardiopulmonary resuscitation (CPR), in favor of continuous chest compressions. This instruction comes following a March 2008 scientific advisory published in the journal Circulation. GivenThe Corticosteroid Journey in PMR: Understanding the Patient Experience
https://reachmd.com/programs/medical-industry-feature/pmr-corticosteroid-patient-experience/39774/Even though corticosteroids can bring quick, symptomatic relief for patients with polymyalgia rheumatica (PMR), their long-term use may be associated with adverse consequences.1-3 But adopting an individualized strategy and exploring alternative therapies can help empower patients to actively engageNavigating Vaccine Communication: A Medical Affairs Perspective
https://reachmd.com/programs/maps-chats/vaccine-communication-medical-affairs/56810/At the intersection of expertise, strategy, and collaboration, medical affairs professionals are translating vaccine science into meaningful and actionable insights for healthcare providers. In this candid conversation from the 2026 Medical Affairs Professional Society (MAPS) Annual Meeting, Dr. MatDWTV Extra: Raising Awareness of GPP
https://reachmd.com/series/dermwire-tv/dwtv-extra-raising-awareness-of-gpp/56366/Shannon Trotter, DO, discusses the importance of awareness of generalized pustular psoriasis (GPP) and targeting IL-36, as well as GPP Awareness Day in August.The Emergence of Targeted Therapies for Prurigo Nodularis
https://reachmd.com/programs/dermatology-hub-neuroimmune-network/the-emergence-of-targeted-therapies-for-prurigo-nodularis/48775/Christopher Bunick, MD, FAAD, discusses the importance of acknowledging prurigo nodularis as a distinct disease with its own molecular and transcriptomic features distinguishing it from atopic dermatitis, and how targeting the IL-31 receptor can change the game.Clinical Conversations: A conversation with Dr Angela Lamb, a dermatologist and professor in New York, New York
https://reachmd.com/programs/nemluvio-peer-network/clinical-conversations-a-conversation-with-dr-angela-lamb-a-dermatologist-and-professor-in-new-york-new-york/37237/Dr Angela Lamb discusses her approach to treating prurigo nodularis (PN) and atopic dermatitis (AD). She’ll explain how NEMLUVIO®, the first and only neuroimmune-targeted therapy that blocks IL-31RA, targets both immune and neuronal pathways and addresses chronic itch, inflammation, and barrier disrAdvances in Psoriasis Treatment: Selecting the Right Biologic Therapy
https://reachmd.com/programs/clinicians-roundtable/advances-in-psoriasis-treatment-selecting-the-right-biologic-therapy/36366/Biologic therapies have helped significantly improve outcomes and quality of life for patients with psoriasis. With several IL-17 and IL-23 inhibitors now available, choosing between biologics often depends on the dermatologist’s experience, the patient’s needs, and potential side effects. Hear Dr.Putting Patients First: Personalized Care in Metastatic Breast Cancer
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/putting-patients-first-personalized-care-in-metastatic-breast-cancer/36435/Metastatic breast cancer treatment isn't one-size-fits-all. Providers must carefully balance clinical outcomes, toxicity, and patient lifestyle and preferences. Dr. Giancarlo Moscol joins Ms. Ashley Baker to outline a structured, three-tiered decision-making process that weighs treatment efficacy, sTreating Osteoporosis in Older Adults: The Limitations of BMD Measurements
https://reachmd.com/programs/frontlines-osteoporosis/treating-osteoporosis-in-older-adults-the-limitations-of-bmd-measurements/32332/Bone mineral density (BMD) is important in assessing fracture risk and determining treatment thresholds for osteoporosis, but there are limitations in accessing BMD measurements in older patients. Here to discuss these challenges is Dr. Cathleen Colón-Emeric, Professor of Medicine and Chief of the DAdvances in Care for ATTR-CM: Current and Emerging Strategies
https://reachmd.com/programs/heart-matters/advances-in-care-for-attr-cm-current-and-emerging-strategies/33061/Increased recognition of transthyretin cardiac amyloidosis has led to a variety of innovative therapies. Here’s what you need to know.